Why global pharmaceutical reforms are quietly redirecting rare disease innovation
Pharmaphorum • Thu Aug 06 2026
For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may have produced a very different outcome three years ago: where to launch first, the EU, UK, or the US?
For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may have produced a very different outcome three years ago: where to launch first, the EU, UK, or the US?
The confluence of three forces — a sweeping overhaul of EU pharmaceutical legislation, intensifying pricing pressure in the UK, and transformative regulatory change in the United States — is quietly recalibrating the calculus for drug makers. For emerging biopharma companies with limited capital and single high-value indications, the once common US-first assumption no longer holds by default. A more nuanced approach to commercial planning that addresses the relative changes in these markets is now a strategic imperative.
Understanding how to best proceed requires an examination and evaluation of what has changed on both sides of the Atlantic.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.